Perianal Fistulas Are Associated with Persistently Higher Direct Health Care Costs in Crohn’s Disease: A Population-Based Study
- 5 October 2023
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (12) , 4350-4359
Abstract
Background The economic impact of perianal fistulas in Crohn’s disease (CD) has not been formally assessed in population-based studies in the biologic era. Aim To compare direct health care costs in persons with and without perianal fistulas. Methods We performed a longitudinal population-based study using administrative data from Ontario, Canada. Adults (> 17 years) with CD were identified between 2007 and 2013 using validated algorithms. Perianal fistula positive “cases” were matched to up to 4 “controls” with CD without perianal fistulas based on age, sex, geographic region, year of CD diagnosis and duration of follow-up. Direct health care costs, excluding drug costs from private payers, were estimated annually beginning 5 years before (lookback) and up to 9 years after perianal fistula diagnosis (study completion) for cases and a standardized date for matched controls. Results A total of 581 cases were matched to 1902 controls. The annual per capita direct cost for cases was similar at lookback compared to controls ($2458 ± 6770 vs $2502 ± 10,752; p = 0.952), maximally greater in the first year after perianal fistulas diagnosis ($16,032 ± 21,101 vs $6646 ± 13,021; p < 0.001) and remained greater at study completion ($11,358 ± 17,151 vs $5178 ± 9792; p < 0.001). At perianal fistula diagnosis, the cost difference was driven primarily by home care cost (tenfold greater), publicly-covered prescription drugs (threefold greater) and hospitalizations (twofold greater), whereas at study completion, prescription drugs were the dominant driver (threefold greater). Conclusion In our population-based cohort, perianal fistulas were associated with significantly higher direct healthcare costs at the time of perianal fistulas diagnosis and sustained long-term. Graphical AbstractKeywords
Funding Information
- Takeda Canada
This publication has 42 references indexed in Scilit:
- A 3-year study of high-cost users of health careCanadian Medical Association Journal, 2016
- The global burden of IBD: from 2015 to 2025Nature Reviews Gastroenterology & Hepatology, 2015
- Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, CanadaJournal of Clinical Epidemiology, 2014
- Health Care Costs of Complex Perianal Fistula in Crohn’s DiseaseDigestive Diseases and Sciences, 2013
- Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)Gut, 2013
- Systematic review: the costs of ulcerative colitis in Western countriesAlimentary Pharmacology & Therapeutics, 2010
- Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative dataGut, 2009
- Effects of fistula on healthcare costs and utilization for patients with Crohnʼs disease treated in a managed care environmentInflammatory Bowel Diseases, 2008
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialThe Lancet, 2008
- Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double‐blind placebo‐controlled studyAlimentary Pharmacology & Therapeutics, 2004